Featured news from NHIVNA
HIV-related news from NAM
Maraviroc may work as PrEP in combination with another drug – but probably not by itself
Gus Cairns, 2016-03-03 14:30:00
Two studies presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2016) outlined the
first findings from the NEXT-PrEP study, otherwise known as HPTN 069. As
its name indicates, it explores the option of using a drug or drugs for
pre-exposure prophylaxis (PrEP) other than tenofovir + emtricitabine (Truvada),
which is currently licensed in the US, France, South Africa, Kenya, Israel and – in
a press release quietly issued on Monday – Canada.
What NEXT-PrEP has discovered so far indicates that the drug
maraviroc (Celsentri, Selzentry)
could have a role in PrEP when used alongside either of the component drugs in Truvada but is not potent enough to act
as PrEP in itself.